Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 LN-145 in recurrent, metastatic, or persistent cervical carcinoma
2016-003447-11Phase 2Unknown
- Sponsor
- Iovance Biotherapeutics
- Start
- Aug 2017
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of LN-145 in Cervical Cancer (CC), sponsored by Iovance Biotherapeutics. Status: unknown.
02
Drugs
LN-145
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2016-003447-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003447-11.